Stanford Researchers Announce Breakthrough in Type 1 Diabetes Remission

Got story updates? Submit your updates here. ›

Researchers at Stanford University have announced a successful method for achieving remission of type 1 diabetes in mice through a double cell transplant procedure. The treatment involves transplanting pancreatic islet cells and blood stem cells, creating a hybrid immune system that prevents the destruction of insulin-producing cells. While still in early stages, this breakthrough offers hope for a future where autoimmune diseases can be effectively treated and potentially cured.

Why it matters

This research represents a significant advancement in the treatment of type 1 diabetes, which has traditionally been a lifelong condition requiring insulin therapy. If proven effective in human trials, this approach could lead to a cure or long-term remission for those living with the autoimmune disease, dramatically improving their quality of life and reducing the burden of daily management.

The details

The Stanford researchers' approach involves a double transplant procedure. First, they transplant pancreatic islet cells, which produce insulin, into the patient. Then, they transplant the patient's own blood stem cells, which have been genetically modified. This creates a hybrid immune system that does not attack the newly transplanted islet cells, preventing the autoimmune destruction that occurs in type 1 diabetes.

• In March 2026, researchers at Stanford University announced the successful method for achieving remission of type 1 diabetes in mice.

What’s next

The researchers at Stanford plan to begin human clinical trials to further test the effectiveness and safety of this double cell transplant procedure for treating type 1 diabetes. If successful, this could lead to a new standard of care for the autoimmune disease.